August 8, 2025 — Capricor Therapeutics (NASDAQ: CAPR) has scheduled a Type A meeting with the FDA to discuss the regulatory path for its BLA for Deramiocel, a cell therapy candidate for cardiomyopathy associated with Duchenne muscular dystrophy (DMD). The company has rescheduled the release of its second-quarter financial results to August 11, 2025, after the market close, with a webcast and conference call at 4:30 p.m. ET.
The conference call can be accessed toll-free at 1-800-717-1738 or internationally at 1-646-307-1865, Conference ID: 90328. A webcast will be available on the company’s website, with a replay following the live broadcast.
Deramiocel is in late-stage development for DMD treatment. Capricor is also using its StealthX™ platform for vaccinology and targeted delivery of therapeutics.
Capricor has an agreement with Nippon Shinyaku Co., Ltd. for the commercialization and distribution of Deramiocel for DMD in the U.S. and Japan, pending regulatory approval.
Raquel Cona, KCSA Strategic Communications, rcona@kcsa.com, 212.896.1204
AJ Bergmann, Chief Financial Officer, abergmann@capricor.com, 858.727.1755
Source: Capricor Therapeutics
